Breast Cancer Diagnostics: Start-Ups Look To Fill Gaps In The Patient Care Continuum

Mammography is a mature and successful breast cancer diagnostic technology, but it has many drawbacks, including high false-negative and false-positive rates, the use of ionizing radiation, and ineffectiveness in dense or scarred breast tissue. Emerging companies aim to improve on this gold standard as well as streamline radiological workflow and predict disease aggressiveness and recurrence. START-UP profiles four such companies in this issue: Delphinus Medical Technologies, Ibris, NovaScan and Real Time Tomography.

A woman born in the US today has a one in eight chance of developing invasive breast cancer during her lifetime. Each year approximately 230,000 new cases are diagnosed and more than 39,000 die from the disease, putting it in second place behind lung cancer as a top cause of cancer deaths for women, according to the National Institutes of Health’s National Cancer Institute. On the positive side, mortality from breast cancer in the US and other industrialized countries has been decreasing at approximately 2.2% per year since 1990, thanks to advances in adjuvant therapy and the increasing use of screening mammography. More than 39 million mammograms will be performed in the US in 2011. Two-dimensional (2D) screen film and full-field digital mammography (FFDM) are the gold standard technologies used in breast cancer screening, with FFDM now being used in approximately 82% of US centers, up from 20% in 2006, according to the latest Mammography Quality Standards Act (MQSA) statistics. Despite mammo being a mature and successful diagnostic technology, in use for over 40 years, there is much room for improvement to address its drawbacks, which include high false-negative and false-positive rates, the use of ionizing radiation, and ineffectiveness in dense or scarred breast tissue.

On the therapeutic side, there is also much room for innovation. Reoperation rates as high as 49% after early-stage breast...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Novel Pathway For Combined Drug/IVD Trials Wins Backing Of EU Nations

 
• By 

Broad participation by EU member states in a new pilot to test a unified procedure for evaluating applications for combined drug and IVD studies shows they recognize its value, says Monique Al, vice-chair of the Clinical Trials Coordination Group.

EU Life Sciences Strategy Must Address ‘Regulatory Lasagna’

 

MedTech Europe is ready to become involved and shape Europe’s Life Sciences Strategy and help drive regulatory simplification from the top to make the EU “the world’s most attractive place for life sciences by 2030.”

Questions Over UK Prevention Agenda Within NHS 10-Year Plan

 
• By 

The UK government’s blueprint to deliver an NHS "fit for the future" was released on July 3.